Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Auranofin is a gold-thiol complex with diverse biological activities.1,2,3 It inhibits thioredoxin reductase (IC50 = 0.2 µM), increases oxidation of mitochondrial peroxiredoxin 3 (PRDX3), and induces apoptosis in Jurkat T cells.1 Auranofin reduces the production of IL-6 and activation of JAK1 and JAK2, as well as inhibits nuclear translocation of NF-kB, in primary human synoviocytes.2 It is active against P. falciparum and S. mansoni in vitro when used at concentrations ranging from 1 to 10 µM. In vivo, auranofin (2 mg/kg per day) reduces the number of peripheral blood mononuclear cells (PBMCs) containing viral DNA and delays viral rebound in macaques infected with the mac251 strain of simian immunodeficiency virus (SIV).3 Auranofin (0.5 µM) synergizes with buthionine sulfoxime (BSO) to decrease glutathione peroxidase 4 (GPX4) levels, increase intracellular accumulation of reactive oxygen species (ROS), and induce ferroptosis in Huh7 and HepG2 hepatocellular carcinoma cells.4
WARNING This product is not for human or veterinary use.
1. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-
2. The biological activity of auranofin: Implications for novel treatment of diseases. Inflammopharmacology 20(6), 297-306 (2012).
3. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 25(11), 1347-1356 (2011).
4. Redox modulation and induction of ferroptosis as a new therapeutic strategy in hepatocellular carcinoma. Transl. Oncol. 13(8), 100785 (2020).
Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability. Nat. Chem. Biol. (2022).
GOT1 inhibition primes pancreatic cancer for ferroptosis through the autophagic release of labile iron. bioRxiv (2020).